Product Description
Product Details
Tirzepatide: It is a dual agonist of the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor. In simple terms, it mimics two crucial intestinal hormones (GIP and GLP-1) and regulates blood sugar, appetite, and metabolism in multiple aspects.
一: Main approved indications
1. Type 2 Diabetes (Mounjaro®):
· By stimulating insulin secretion, inhibiting glucagon secretion, and delaying gastric emptying, it efficiently lowers blood sugar (HbA1c).
· The effect is superior to other similar drugs (such as semaglutide) in clinical trials.
2. Obesity or overweight with weight-related comorbidities (Zepbound®):
· By acting on the appetite center in the brain, it significantly increases satiety and reduces hunger, thereby reducing calorie intake.
· In clinical trials, it shows excellent weight loss effects, with an average weight reduction of up to 15%-20% (combined with diet and exercise).
二: Key Data and Results
· Hypoglycemic effect: In the SURPASS series of clinical trials, the hypoglycemic effect was superior to that of insulin and GLP-1 single receptor agonists.
· Weight loss effect: In the SURMOUNT series of clinical trials, at 72 weeks, patients using the highest dose (15mg) achieved an average weight loss of 20.9% (compared to the placebo group).
· Cardiovascular benefits: The latest research (SURPASS-CVOT) shows that for type 2 diabetic patients with cardiovascular diseases and obesity, compared to insulin, Tirzepatide can significantly reduce the risk of major adverse cardiovascular events by 20%, while significantly reducing weight.
Administration method
· Formulation: Subcutaneous injection pen.
· Frequency: Once a week.
· Dosage: It should be gradually titrated from a low dose to reduce gastrointestinal side effects. There are multiple dosage specifications (2.5mg, 5mg, 7.5mg, 10mg, 12.5mg, 15mg).
三: Future and Impact
Tirzepatide represents a new direction in the development of "dual" and potentially future "multi-agonist" drugs. Its potent efficacy is redefining the management goals for type 2 diabetes and obesity, and bringing new hope for the treatment of related metabolic diseases (such as NASH - non-alcoholic fatty liver disease, sleep apnea, etc.).
Company Profile
Nanjing Shuangxindashi Trading Co., Ltd. is dedicated to the production and sales of intermediates and peptides, as well as the research and development of new materials such as bodybuilding and shaping, interesting compounds, weight loss, anti-aging, digestive tract disease regulation, and immunity enhancement. We provide professional services including raw materials, resources, and customized production. We are particularly proud of our partnerships in high-quality ingredient and raw material production to meet the needs of our diverse customers.
